Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 5.6% from a year ago

Cash & equivalents stood at $28.66M at the end of Q1 FY2026, down 5.6% from a year earlier and up 43.6% from the prior quarter. Over 3 fiscal years it compounded at -23.9% a year.

Context

  • Cash & equivalents amounted to 14.4% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -5.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.66M+43.6% QoQ
Last fiscal yearDec 2025
$19.96M-18.8% YoY
Year agoMar 2025
$30.36M-5.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.6%——
1 year-18.8%——
3-year CAGR-23.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
19.96M USD
Year-over-year change
-18.8%
4-year CAGR
-7.6%

Cash & Equivalents vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -5.6% is the 5th highest of 7, against a peer median of +19.5%.
  • Cash & equivalents amounts to 14.4% of total assets for ACRS, versus a peer median of 75.4%.
ACRS Competitors
Cash & Equivalents for ACRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$298.49M USD+9.9%+103.8%74.6%
TRAXFirst Tracks Biotherapeutics IncMar 2026$248.47M USD——85.5%
ANABAnaptysBio, Inc.Mar 2026$248.47M USD+151.9%+49.5%75.4%
IMUXImmunic, Inc.Mar 2026$186.63M USD+1204.7%-47.5%98.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€129.59M EUR——78.2%
ALDXAldeyra Therapeutics, Inc.Mar 2026$65M USD+29.1%-21.4%97.8%
ALMSAlumis Inc. Common StockJun 2026$63.71M USD-58.0%+51.8%11.4%
ATTOAttovia Therapeutics, Inc.Jun 2026$32.83M USD——25.6%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M USD-5.6%-23.9%14.4%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+19.5%+24.5%75.4%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.35M45.28M39.88M24.57M19.96M
Short-term Investments164.07M172.29M79.23M89.02M70.79M
Net Receivables623K484K298K318K5.57M
Inventory00000
Other Current Assets013.5M9.45M12.04M55.05M
Total Current Assets205.03M231.55M128.86M125.95M151.36M
Property, Plant & Equipment (Net)1.34M1.1M1.62M1.01M0
Goodwill00000
Intangible Assets7.05M6.97M269K00
Long-term Investments34.24M12.24M62.77M90.3M60.61M
Tax Assets00000
Other Non-current Assets3.55M2.73M3.89M3.07M(51.52M)
Total Non-current Assets46.18M23.05M68.55M94.38M9.1M
Total Assets251.21M254.6M197.41M220.33M160.46M
Account Payables9.99M10.35M8.88M4.69M13.16M
Short-term Debt0000551K
Tax Payables00000
Deferred Revenue0003.89M3.94M
Other Current Liabilities6.59M7.5M6.11M11.59M5.7M
Total Current Liabilities22.93M21.94M30.95M31.6M28.65M
Long-term Debt00000
Deferred Tax Liabilities367K367K000
Deferred Revenue (Non-current)00020.04M16.17M
Other Non-current Liabilities30.57M34.67M9.27M13.14M11M
Total Non-current Liabilities30.94M35.04M9.27M33.18M28.73M
Total Liabilities53.87M56.98M40.23M64.77M57.38M
Common Stock1K1K1K1K1K
Retained Earnings(595.41M)(682.32M)(770.8M)(902.86M)(967.78M)
Accumulated OCI(224K)(897K)(106K)97K610K
Other Stockholders Equity00000
Minority Interest00000
Total Equity197.34M197.62M157.18M155.55M103.08M
Total Debt693K684K426K02.12M
Net Debt(26.66M)(44.59M)(39.45M)(24.57M)(17.84M)

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.